BiotechTube
Home/Pipeline/I&I Portfolio

I&I Portfolio

Autoimmune Diseases

Pre-clinicalActive

Key Facts

Indication
Autoimmune Diseases
Phase
Pre-clinical
Status
Active
Company
Third Arc Bio

About Third Arc Bio

Third Arc Bio is a private, preclinical-stage biotech pioneering a new class of multifunctional antibody therapeutics, which it terms the 'Third Arc' of biologics. The company's platform is designed to engineer optimized biologics that engage multiple targets and cell types by leveraging immune synapse biology, aiming to overcome limitations in treating solid tumors and autoimmune diseases. Led by a seasoned team with a collective history of over 35 drug approvals, the company is backed by venture capital and is actively building its pipeline. Its recent Series A extension provides capital to grow its oncology and I&I portfolios.

View full company profile

Therapeutic Areas

OncologyImmunology & Inflammation

Other Autoimmune Diseases Drugs

DrugCompanyPhase
Humira (Adalimumab) BiosimilarNeuCloneEarly Preclinical
HBM7020Harbour BioMedDiscovery
R2006Harbour BioMedDiscovery
R7027Harbour BioMedDiscovery
ImmCelz™ PlatformCreative Medical Technology HoldingsPreclinical
Not specified in provided content3SbioVarious
Gavocabtagene autoleucelastellasPhase 1/2
TYK-101TYK MedicinesPhase 1
HCB206HanchorBioPreclinical
miR-124 ActivatorFormation BioPhase 2
Autologous Cell Therapy CollaborationLupagenPreclinical
Autoimmune Diagnostics Leadership InitiativeVibrant America Clinical LaboratoryCommercial